SEAL1

SEAL1 is a therapeutic antisense oligonucleotide (ASO) designed to target the long non-coding RNA (lncRNA) SEAL1. SEAL1 is a master regulator of the myofibroblast-like cancer-associated fibroblast (myCAF) cell state, which contributes to the desmoplastic reaction, immune suppression, and treatment resistance in the solid tumor microenvironment. By inhibiting SEAL1, the ASO reduces the pro-tumorigenic identity of myCAFs, leading to decreased tumor volume and potentially enhancing the efficacy of immunotherapies. The program is being developed for the treatment of various solid cancers, including breast, lung, head and neck, and pancreatic cancer.